Please use this identifier to cite or link to this item: https://scholarhub.balamand.edu.lb/handle/uob/5904
DC FieldValueLanguage
dc.contributor.authorShaib, Walid Len_US
dc.contributor.authorNammour, Jean Paul Aen_US
dc.contributor.authorGill, Harpaulen_US
dc.contributor.authorMody, Mayuren_US
dc.contributor.authorSaba, Nabil Fen_US
dc.date.accessioned2022-07-26T06:41:49Z-
dc.date.available2022-07-26T06:41:49Z-
dc.date.issued2016-01-14-
dc.identifier.issn2077-0383-
dc.identifier.urihttps://scholarhub.balamand.edu.lb/handle/uob/5904-
dc.description.abstractThe prognosis of esophageal cancers is poor and novel approaches are urgently needed. Despite improvements in outcomes with transtuzumab and ramucirumab, these improvements added an average of only 2 to 3 months with a median overall survival reported to be around 1 year. Comprehensive genomic sequencing has defined some molecular alterations with potential targets, but the majority of patients still do not benefit from druggable targets. Breakthroughs in immune checkpoint blockade have provided new therapeutic options in many cancers. Programmed death ligand 1 (PDL1) overexpression, a possible biomarker predicting response to immune checkpoint inhibitors, approaches forty percent in esophageal and gastric cancers. Translational and molecular studies have shown that esophageal cancers are possible candidate malignancies for immune checkpoint inhibition. In this review, we plan to highlight the mechanisms, preclinical, and early clinical data that provide insight on the role of immune therapeutics in esophageal cancers.en_US
dc.language.isoengen_US
dc.publisherNational Library of Medicineen_US
dc.subjectEsophageal canceren_US
dc.subjectImmune therapyen_US
dc.subjectProgressen_US
dc.titleThe Future Prospects of Immune Therapy in Gastric and Esophageal Adenocarcinomaen_US
dc.typeJournal Articleen_US
dc.identifier.doi10.3390/jcm5110100-
dc.identifier.pmid27854242-
dc.identifier.scopus2-s2.0-85065795211-
dc.identifier.urlhttps://api.elsevier.com/content/abstract/scopus_id/85065795211-
dc.contributor.affiliationFaculty of Medicineen_US
dc.description.volume5en_US
dc.description.issue11en_US
dc.date.catalogued2022-07-26-
dc.description.statusPublisheden_US
dc.identifier.openURLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5126797/en_US
dc.relation.ispartoftextJournal of Clinical Medicineen_US
dc.description.campusSGH campusen_US
Appears in Collections:Faculty of Medicine
Show simple item record

SCOPUSTM   
Citations

7
checked on Oct 1, 2022

Record view(s)

5
checked on Oct 7, 2022

Google ScholarTM

Check

Dimensions Altmetric

Dimensions Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.